PMC:7195088 / 18334-18535 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"663","span":{"begin":103,"end":111},"obj":"Species"},{"id":"762","span":{"begin":16,"end":35},"obj":"Chemical"},{"id":"924","span":{"begin":117,"end":125},"obj":"Disease"}],"attributes":[{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"Tax:9606"},{"id":"A762","pred":"tao:has_database_id","subj":"762","obj":"MESH:C558899"},{"id":"A924","pred":"tao:has_database_id","subj":"924","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to comple"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T90","span":{"begin":117,"end":125},"obj":"Disease"}],"attributes":[{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"rferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to comple"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T94","span":{"begin":132,"end":137},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"rferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to comple"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T156","span":{"begin":16,"end":35},"obj":"Chemical"},{"id":"T157","span":{"begin":16,"end":25},"obj":"Chemical"},{"id":"T158","span":{"begin":26,"end":35},"obj":"Chemical"},{"id":"T159","span":{"begin":49,"end":59},"obj":"Chemical"},{"id":"T160","span":{"begin":132,"end":137},"obj":"Chemical"}],"attributes":[{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"rferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to comple"}

{"project":"LitCovid-sentences","denotations":[{"id":"T124","span":{"begin":127,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to comple"}